Floatz logo

Tas-102

Clear Cell Renal Cell Carcinoma

National Cancer Institute (NCI)unclassifiedPhase 3Dormant
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
55/ 100
Competitive Position
73/ 100

Competitive context

63 Active assets in the Clear Cell Renal Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Girentuximab
Massachusetts General Hospital
Phase 3BB
gw786034
Academic and Community Cancer Research United
Phase 4BB
su011248
Pfizer
Phase 4BB
Nivolumab
Fred Hutchinson Cancer Center
Phase 3BB
Bms-907351
SWOG Cancer Research Network
Phase 3BB

View all 50 →

Same molecule, other indications

Tas-102 is also rated in:

Stage IV Non-Small Cell Lung Cancer AJCC v7Dormant
BB
Indicative ·
68 / 100
View asset →
Stage IV Renal Cell CancerDormant
BB
Indicative ·
68 / 100
View asset →
Carcinoma, Islet CellDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →